Transformative Partnership: Zydus and Guardant Health Join Forces for Cancer Testing in India and Nepal

▴ Cancer Testing in India
As India and Nepal grapple with the growing burden of cancer cases, initiatives like these are pivotal in steering the healthcare landscape towards innovative solutions and improved patient care

In a remarkable move towards advancing precision medicine, Zydus and Guardant Health have entered into a co-marketing agreement, aiming to promote the Guardant360 portfolio of liquid and tissue biopsy tests across India and Nepal. This collaboration, as announced through an exchange filing, highlights the commitment to enhancing patient outcomes and the field of precision oncology in the region.

Comprehensive Genomic Profiling at the Forefront: The tests highlighted in this partnership include Guardant360 and Guardant360 TissueNext, offering comprehensive genomic profiling (CGP), along with the Guardant360 Response test designed for monitoring treatment response. These cutting-edge tests play a crucial role in providing oncologists with valuable insights to make informed decisions for patients dealing with advanced cancer.

Addressing a Growing Health Challenge: Cancer poses a significant health challenge in India and Nepal, with alarming statistics revealing that one out of nine Indians may develop cancer in their lifetime, and over 20,000 individuals in Nepal are diagnosed with cancer annually. Simranjit Singh, CEO of Guardant Health Asia, Middle East, and Africa, emphasizes the pressing need to tackle this issue.

Innovative Solutions for Improved Patient Care: Guardant360, a minimally invasive liquid biopsy test, stands out by offering comprehensive genomic profiling of solid tumours through the analysis of circulating tumour DNA (ctDNA) from a simple blood draw. Guardant360 TissueNext complements this by providing CGP results from a tumour tissue biopsy, offering actionable information to doctors when tissue testing is necessary. The Guardant360 Response test serves as a vital monitoring tool, enabling oncologists to track a patient's treatment response over time.

A Collective Step Toward Precision Medicine: By pooling their resources and expertise, Zydus and Guardant Health aspire to empower oncologists with the necessary tools to navigate treatment decisions effectively. This collaboration signifies a shared dedication to advancing precision medicine and ultimately making a positive impact on cancer care in the region.

As India and Nepal grapple with the growing burden of cancer cases, initiatives like these are pivotal in steering the healthcare landscape towards innovative solutions and improved patient care. The collaboration between Zydus and Guardant Health marks a significant stride in the realm of precision medicine, offering a ray of hope for cancer patients in India and Nepal. With a focus on comprehensive genomic profiling through tests like Guardant360 and Guardant360 TissueNext, the collaboration addresses the pressing need for precise and informed decision-making in oncology. The inclusion of the Guardant360 Response test further underlines the commitment to monitoring treatment responses over time, ensuring a tailored approach to each patient's journey.

Tags : #zydus #guardanthealth #india #nepal #cancer #cancertesting #patientcare #cancerawareness #medicircle

About the Author

Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...


Trending Now

Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023
Revolutionary AI-powered technology detects multiple abdominal pathologies simultaneouslyNovember 16, 2023
1 Out of 3 Stroke Patients Suffer Long-Term Health Complications, Says NeurologistNovember 16, 2023
Amrita Hospital, Kochi, Launches App for People with Swallowing DifficultiesNovember 15, 2023